"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
| Descriptor ID |
D001682
|
| MeSH Number(s) |
G03.787.151 G07.690.725.129
|
| Concept/Terms |
Biological Availability- Biological Availability
- Availability, Biological
- Availabilities, Biological
- Biological Availabilities
- Biologic Availability
- Physiologic Availability
- Availability, Biologic
- Availabilities, Biologic
- Biologic Availabilities
- Bioavailability
- Bioavailabilities
- Availability, Physiologic
- Availabilities, Physiologic
- Physiologic Availabilities
Availability Equivalency- Availability Equivalency
- Availability Equivalencies
- Equivalencies, Availability
- Equivalency, Availability
|
Below are MeSH descriptors whose meaning is more general than "Biological Availability".
Below are MeSH descriptors whose meaning is more specific than "Biological Availability".
This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 5 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Availability" by people in Profiles.
-
Relative Bioavailability Assessment of Solid Forms by An Artificial Stomach and Duodenum Apparatus. J Pharm Sci. 2024 Aug; 113(8):2506-2512.
-
A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice. Nat Biomed Eng. 2024 May; 8(5):611-627.
-
Development of direct compression Acetazolamide tablet with improved bioavailability in healthy human volunteers enabled by cocrystallization with p-Aminobenzoic acid. Int J Pharm. 2024 Mar 05; 652:123793.
-
Fabrication of solid lipid nanoparticles-based patches of paroxetine and their ex-vivo permeation behaviour. Artif Cells Nanomed Biotechnol. 2023 Dec; 51(1):108-119.
-
Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization. Int J Pharm. 2022 Mar 25; 616:121541.
-
Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. Int J Pharm. 2021 Dec 15; 610:121216.
-
Novel Salt-Cocrystals of Berberine Hydrochloride with Aliphatic Dicarboxylic Acids: Odd-Even Alternation in Physicochemical Properties. Mol Pharm. 2021 04 05; 18(4):1758-1767.
-
In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma. Aging (Albany NY). 2020 11 16; 12(22):22949-22974.
-
Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts. Int J Pharm. 2020 Mar 15; 577:119089.
-
Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta. 2018 Aug; 483:308-314.